Results 181 to 190 of about 27,903 (211)
Some of the next articles are maybe not open access.
Biochemical modulation of cytosine arabinoside
Pharmacology & Therapeutics, 19901-beta-D arabinofuranosylcytosine (ara-C) is an analog of the naturally occurring nucleoside 2'-deoxycytidine which is a potent antileukemic agent in man. Because the metabolism (and, ultimately, the effectiveness) of this agent is regulated by multiple processes involved in pyrimidine biosynthesis, attempts to improve its efficacy through biochemical ...
openaire +2 more sources
Toxicity of Adenine Arabinoside in Humans
Journal of Infectious Diseases, 1976Six forms of reversible adverse reactions to adenine arabinoside (vidarabine) were observed in a two-year period among 42 patients (19 of whom had lymphomas, leukemias, or other malignancies) who were treated for complicated infections with varicella-zoster or herpes simplex virus. Six patients received placebo.
A H, Ross, A, Julia, C, Balakrishnan
openaire +2 more sources
Biochemical pharmacology of cytosine arabinoside
Medical and Pediatric Oncology, 1982Cytosine arabinoside (Ara-C) is a very potent inhibitor of DNA synthesis in mammalian cells. This inhibition does not appear to be due to the direct inhibition of DNA polymerase by Ara-CTP (triphosphate of Ara-C) because it is a very weak competitive inhibitor of this enzyme. The inhibition of DNA synthesis appears to be due to the incorporation of Ara-
openaire +2 more sources
In vitro cytostatic effect of adenine-arabinoside (Ara-A) and cytosine-arabinoside (Ara-C)
Experientia, 1978Adenine-arabinoside, a new antiviral drug with questionable bone marrow toxicity, inhibits colony formation by myeloid precursor cells in vitro. Compared to cytosine-arabinoside this cytotoxicity is roughly one third.
C, Nissen, J, Henauer, B, Speck
openaire +2 more sources
The cytosine arabinoside (Ara‐C) syndrome
Medical and Pediatric Oncology, 1981AbstractFour patients with non‐Hodgkin lymphoma and two with acute lymphocytic leukemia (ages 4 years 4 months to 16 years 6 months) exhibited a unique reaction to intravenously administered cytosine arabinoside (Ara‐C) given alone as a part of the previously reported LSA2‐L2 treatment protocol.
R P, Castleberry +4 more
openaire +2 more sources
TREATMENT OF SMALLPOX WITH CYTOSINE ARABINOSIDE
The Lancet, 1972Abstract During the recent outbreak in Bangladesh, nine patients with smallpox were treated with cytosine arabinoside in an uncontrolled trial. Prompt clinical responses were seen in most patients, and only one patient died. In contrast forty-two out of ninety-seven untreated patients in the same district died.
M S, Hossain +5 more
openaire +2 more sources
N4-chloroacetylcytosine arabinoside--a possible pro-drug of cytosine arabinoside.
Biochemistry international, 1988Lipophilic N4-acetyl (1b-d) and N4-chloroacetyl (2b-d) derivatives of cytidine, 2'-deoxycytidine and cytosine arabinoside (ara-C) were synthesized and their toxicity for A(T1)Cl-3 hamster fibrosarcoma cells determined. 2b-d proved potent with no colonies surviving at concentrations of 10(-4), 10(-4) and 10(-6) M, respectively. lb-d showed comparatively
M, Ariatti, P A, Jones
openaire +1 more source
Therapy of chronic type B hepatitis with adenine arabinoside and adenine arabinoside monophosphate
Journal of Hepatology, 1986Adenine arabinoside (ARA-A) and its monophosphate (ARA-AMP) are potent inhibitors of hepatitis B virus, but they have not been shown to beneficially alter the natural history of chronic type B hepatitis. Analysis of responders to ARA-AMP therapy has shown that responses can be temporary and that truly long-term beneficial responses are rare.
openaire +2 more sources
VARICELLA AND CYTOSINE ARABINOSIDE
The Lancet, 1970B R, Seligman, F, Rosner
openaire +4 more sources